Stereotactic body radiotherapy for localized prostate cancer: disease control and quality of life at 6 years. - Wikidata - wikimedia - TriplyDB

Stereotactic body radiotherapy for localized prostate cancer: disease control and quality of life at 6 years.

Stereotactic body radiotherapy for localized prostate cancer: disease control and quality of life at 6 years.

http://www.wikidata.org/entity/Q41895986

about

The Role of Hypofractionated Radiation Therapy with Photons, Protons, and Heavy Ions for Treating Extracranial Lesions Emergence of stereotactic body radiation therapy and its impact on current and future clinical practice Therapeutic usability of two different fiducial gold markers for robotic stereotactic radiosurgery of liver malignancies: A pilot study.The RSSearch™ Registry: patterns of care and outcomes research on patients treated with stereotactic radiosurgery and stereotactic body radiotherapy Clinical characteristics and management of late urinary symptom flare following stereotactic body radiation therapy for prostate cancer External beam techniques to boost cervical cancer when brachytherapy is not an option-theories and applications Patient-reported urinary incontinence following stereotactic body radiation therapy (SBRT) for clinically localized prostate cancer.Obstructive voiding symptoms following stereotactic body radiation therapy for prostate cancer.Quality of Life and Toxicity after SBRT for Organ-Confined Prostate Cancer, a 7-Year Study.SBRT for the Primary Treatment of Localized Prostate Cancer: The Effect of Gleason Score, Dose and Heterogeneity of Intermediate Risk on Outcome Utilizing 2.2014 NCCN Risk Stratification Guidelines.Stereotactic Body Radiation Therapy for Prostate Cancer: Review of Experience of a Multicenter Phase I/II Dose-Escalation Study Proctitis following stereotactic body radiation therapy for prostate cancer Multi-institutional registry for prostate cancer radiosurgery: a prospective observational clinical trial.Stereotactic Body Radiation Therapy for Prostate Cancer: What is the Appropriate Patient-Reported Outcome for Clinical Trial Design?Prostate-specific antigen kinetics after primary stereotactic body radiation therapy using CyberKnife for localized prostate cancer.Sexual, irritative, and voiding outcomes, following stereotactic body radiation therapy for prostate cancer.Stereotactic body radiation therapy for prostate cancer patients with old age or medical comorbidity: a 5-year follow-up of an investigational study.Prostate-specific antigen kinetics after stereotactic body radiotherapy as monotherapy or boost after whole pelvic radiotherapy for localized prostate cancer.Stereotactic Body Radiotherapy for Clinically Localized Prostate Cancer: Toxicity and Biochemical Disease-Free Outcomes from a Multi-Institutional Patient Registry.Prostate-specific antigen kinetics following hypofractionated stereotactic body radiotherapy boost as post-external beam radiotherapy versus conventionally fractionated external beam radiotherapy for localized prostate cancer Dosimetric benefits of hemigland stereotactic body radiotherapy for prostate cancer: implications for focal therapy.Stereotactic body radiotherapy with or without external beam radiation as treatment for organ confined high-risk prostate carcinoma: a six year study.Prostate-specific antigen bounce following stereotactic body radiation therapy for prostate cancer.Hypofractionated stereotactic body radiotherapy in low- and intermediate-risk prostate carcinoma Rectal/urinary toxicity after hypofractionated vs conventional radiotherapy in low/intermediate risk localized prostate cancer: systematic review and meta analysis.Potency preservation following stereotactic body radiation therapy for prostate cancer.Rationale for stereotactic body radiation therapy in treating patients with oligometastatic hormone-naïve prostate cancer.A clinical review on extreme hypofractionated stereotactic body radiation therapy for localized prostate cancer using nonrobotic linear accelerators.Emerging applications of stereotactic body radiotherapy.Stereotactic body radiotherapy for primary prostate cancer: a systematic review.Stereotactic body radiation therapy (SBRT) for prostate cancer in men with large prostates (≥50 cm(3)).Hypofractionated radiotherapy for prostate cancer.Potential applications of image-guided radiotherapy for radiation dose escalation in patients with early stage high-risk prostate cancer.Clinical trials of stereotactic ablative radiotherapy for prostate cancer: updates and future direction.Dysuria Following Stereotactic Body Radiation Therapy for Prostate Cancer Quality of life outcomes from a dose-per-fraction escalation trial of hypofractionation in prostate cancer.SBRT and extreme hypofractionation: A new era in prostate cancer treatments?Hypofractionated stereotactic body radiotherapy for localized prostate cancer - first Nordic clinical experience.Late urinary toxicity modeling after stereotactic body radiotherapy (SBRT) in the definitive treatment of localized prostate cancer.Toxicity and efficacy of three dose-fractionation regimens of intensity-modulated radiation therapy for localized prostate cancer.

P2860

Q26770254-03C1E4C6-F9E7-4DF0-B08C-34440812A10B Q27015651-C664EBA4-79E0-430C-9EA6-5FA05E044A00 Q30381174-A17EF6B8-7487-42AE-8A47-12EEA35A8EEC Q30443893-6D46C66F-1816-4E78-8994-1307D130738A Q33659901-2CD58321-3649-4618-A4AE-A0A1B649F483 Q33747597-AF5DAA3F-8B2C-400B-891A-03DA36960C94 Q33851417-4D7C4C7B-B09B-445A-98A8-844AF9014C56 Q33985573-1D67365F-010E-4D94-8D98-884DFBE22CAE Q34413524-F425B9B1-B6B7-4092-8A83-45591685C24E Q34487782-85045D04-8FE3-4B30-AA6A-450D0EE5407A Q34575533-2E2A0E3F-912F-461B-8442-2CAC39156371 Q34748877-C99430F4-024F-4541-9CCA-8F41639FDE50 Q34999092-C8ADDA61-F085-4445-923B-703E9E63583B Q35233601-A056E6C6-F8CA-4E66-B959-18E232752C68 Q35827490-929F771D-B8ED-47A7-BE6E-071F1FCB66FE Q36009944-C6DD00F0-B81A-413D-8E98-C1D686C5B320 Q36154146-72F818F8-8E79-4A39-A39B-3360ED8258C4 Q36387814-22409DB0-B3E0-4915-8B22-3A96BDB6862F Q36426682-CE179AD3-2FBC-4B6F-BA61-3EB55F2F1393 Q36680609-39D5094C-842E-43E8-9622-D6632ACF9537 Q37175207-68B838B6-4E99-4F49-948F-339C950DEBB7 Q37512971-549B6DAA-194F-4468-8E01-E09CB0287F98 Q37522643-402D77F5-B91D-460E-B0FC-DB9DF23131FB Q37551757-1FD2C02D-1038-4D85-BE49-7D208E0456DB Q37725623-B5F1F488-EFC0-404B-AFAC-A0AA2AD05930 Q38158080-1D7B71F2-E3B1-4400-B71D-048A9C863F5C Q38172209-7A4B50BB-FD8E-4333-AADE-A3BE734BF2A3 Q38198096-A21C5477-4846-40BC-B41F-6EB36E528C0E Q38221693-E5FFFA8D-1F87-4D11-A3FD-0C9F8B73B8DC Q38243077-9C0B6DCD-F38D-4614-A129-6796CC803992 Q38268325-2BFDD171-CDEC-4620-B222-A49142FC6B30 Q38283897-D8D96C7C-F11D-4246-86D7-59E8C3D22823 Q38362692-DE03EBC8-229E-4BDF-83AB-2ED23C3870A1 Q38372450-59531466-01D6-41B8-9C50-6882A5098F4B Q38550590-9705C793-813D-47BE-B1EE-E7507687D6B7 Q38603388-056AC327-0F24-456D-95BD-83AEAB8EA407 Q38677018-95BC2EAE-B7D8-4AD1-9CB4-3E6DEE88AFBE Q38780363-84A52F3D-E14D-4C45-8D11-729B0B6EA742 Q39007067-B1F2D1B5-B70F-4F8B-80FB-8ED83699B931 Q39375431-4CD72AC2-C2B7-4290-9544-20E4EA694241

P2860

Stereotactic body radiotherapy for localized prostate cancer: disease control and quality of life at 6 years.

http://www.wikidata.org/entity/Q41895986

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

2013年论文

@zh

2013年论文

@zh-cn

name

Stereotactic body radiotherapy ...... nd quality of life at 6 years.

@en

type

label

Stereotactic body radiotherapy ...... nd quality of life at 6 years.

@en

prefLabel

Stereotactic body radiotherapy ...... nd quality of life at 6 years.

@en

P1433

Q41895986-802EAC76-104E-41BC-A95E-69FA35335C5F

P1476

Q41895986-8081A321-32B0-41D1-BA88-A64923106E8F

P2093

Q41895986-13AD0F57-8EB5-4CFB-9B13-5D38F8D075BE

Q41895986-254511DB-729E-46E3-9B3A-358141FD0DAB

Q41895986-D2A4110E-544E-474F-9276-02E918CA8A45

Q41895986-E520DE2B-FBC2-479F-848E-D151915E6144

P2860

Q41895986-02223EE7-8736-4E0E-A3FC-2DC479E1C689

Q41895986-06CBD866-0914-479C-A839-BE3F98061C9F

Q41895986-1867490D-55A1-4A66-A4DD-E0B547F0F8A9

Q41895986-2143812E-FC5D-493F-861F-6E82D4AF2FC7

Q41895986-352282F2-90BA-4ACB-BC0A-EC4D9BAE6E6D

Q41895986-56004157-9F6A-4689-9C74-A74B76EEEC5F

Q41895986-590690C2-2149-4A66-8CB9-48AA0D08D8B7

Q41895986-616E95C4-2BF7-4E83-A955-77C4BA09BD21

Q41895986-63E752FC-B870-4D7E-A2FE-98DF23359598

Q41895986-76D5C6A3-0737-4564-B98A-721312F15160

P2888

Q41895986-6942670F-95CE-4382-AB99-1ED92097024C

P304

Q41895986-A39853AB-4607-471F-BCD5-992981C2DC44

P31

Q41895986-E53E2AF1-43C8-4479-903D-94AD961EBAFC

P356

Q41895986-89A4DC04-0388-4821-8F2F-CAA587D436CA

P478

Q41895986-D0518DCF-2214-4149-BE5C-77960371EED9

P577

Q41895986-3400FA04-7C62-4188-9E87-3CADA8E2EF54

P5875

Q41895986-BA242869-D091-4EC8-A351-A41EAD5A0FD6

P6179

Q41895986-9067F299-F37A-4BBA-83EE-C9244CB97EEC

P698

Q41895986-D453FCF0-5372-4182-BE99-64F93FA19345

P921

Q41895986-F178CEB4-AA6D-4E21-B65F-73B30FCD1CAC

P932

Q41895986-919EE73C-358C-42ED-866A-EE48BAA4112E

P356

1748-717X-8-118

P1433

Radiation Oncology

P1476

Stereotactic body radiotherapy ...... nd quality of life at 6 years.

@en

P2093

Alan J Katz

http://www.w3.org/2001/XMLSchema#string

Fred Diblasio

http://www.w3.org/2001/XMLSchema#string

Michael Santoro

http://www.w3.org/2001/XMLSchema#string

Richard Ashley

http://www.w3.org/2001/XMLSchema#string

P2860

Stereotactic body radiotherapy for organ-confined prostate cancer.

CyberKnife stereotactic radiotherapy as monotherapy for low- to intermediate-stage prostate cancer: early experience, feasibility, and tolerance.

Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference.

Meta-analysis of rates of erectile function after treatment of localized prostate carcinoma.

High-dose-rate intensity-modulated brachytherapy with external beam radiotherapy for prostate cancer: California endocurietherapy's 10-year results.

Image-guided radiosurgical ablation of intra- and extra-cranial lesions.

Stereotactic body radiotherapy for low-risk prostate cancer: five-year outcomes.

Comparison of quality of life after stereotactic body radiotherapy and surgery for early-stage prostate cancer.

Stereotactic Body Radiation Therapy for Low- and Low-Intermediate-Risk Prostate Cancer: Is there a Dose Effect?

Hypofractionated versus conventionally fractionated radiation therapy for prostate carcinoma: updated results of a phase III randomized trial.

P2888

1748-717x-8-118

P304

118

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/1748-717X-8-118

http://www.w3.org/2001/XMLSchema#string

P478

8

http://www.w3.org/2001/XMLSchema#string

P577

2013-05-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

236738575

http://www.w3.org/2001/XMLSchema#string

P6179

1004741876

http://www.w3.org/2001/XMLSchema#string

P698

23668632

http://www.w3.org/2001/XMLSchema#string

P921

radiation therapy

P932

3674983

http://www.w3.org/2001/XMLSchema#string